HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma. (12th February 2019)

• Record Type: Journal Article
• Authors: Wang, Yanbin; Jiang, Zhaoqiang; Yan, Jianing; Ying, Shibo
• Other Names: Sapin Vincent Academic Editor.
• Is Part Of: Disease markers. Volume 2019(2019)
• Publication Date: 2019-02-12
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2019/4183157
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Malignant mesothelioma (MM) is a rare, aggressive, and highly lethal cancer that is substantially induced by exposure to asbestos fibers. High-mobility group box 1 (HMGB1) is an intriguing proinflammatory molecule involved in MM. In this review, we describe the possible crucial roles of HMGB1 in carcinogenic mechanisms based on in vivo and in vitro experimental evidence and outline the clinical findings of epidemiological investigations regarding the possible roles of HMGB1 as a biomarker for MM. We conclude that novel strategies targeting HMGB1 may suppress MM cells and interfere with asbestos-induced inflammation.